KR950032278A - 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도 - Google Patents

사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도 Download PDF

Info

Publication number
KR950032278A
KR950032278A KR1019950003516A KR19950003516A KR950032278A KR 950032278 A KR950032278 A KR 950032278A KR 1019950003516 A KR1019950003516 A KR 1019950003516A KR 19950003516 A KR19950003516 A KR 19950003516A KR 950032278 A KR950032278 A KR 950032278A
Authority
KR
South Korea
Prior art keywords
peptide
peptide according
amino acid
following amino
retroviruses
Prior art date
Application number
KR1019950003516A
Other languages
English (en)
Other versions
KR100230880B1 (ko
Inventor
브루스트 스테판
크냅 스테판
게르켄 만프레트
게. 귀르틀러 루츠
Original Assignee
부크, 파일
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6510992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950032278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 부크, 파일, 베링베르케 아크티엔게젤샤프트 filed Critical 부크, 파일
Publication of KR950032278A publication Critical patent/KR950032278A/ko
Application granted granted Critical
Publication of KR100230880B1 publication Critical patent/KR100230880B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은, MVP5180/91로 명명되었고 ECACC(european Collection of Animal Cell Cultures)에 기탁번호 V 920 92 318 로 기탁된 신규한 면역결핍증 바이러스로부터 유래된 면역학적으로 활성인 펩타이드에 관한 것이다. 이들 펩타이드는, 특히 면역결핍증 질환과 관련된 레트로바이러스에 대한 항체를 검출하는데 사용된다.

Description

사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩자이드 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 사람 면역결핍 바이러스(HIV) 타입 레트로바이러스의 게놈 배열을 나타낸다. 제2도는 항원/항체 반응으로 수득한 역전사효소 활성과 항원 농도의 관계를 나타낸다. 제3도는 HIV-1 분리물 ARV-2의 서열과 재조합 플라스미드 pSEM 41/3-III에서 발현된 MVP5180 gp41의 서열을 나타낸다.

Claims (18)

  1. 다음의 아미노산 서열로부터 선택된 약 15개 내지 약 50개의 연속한 아미노산 서열을 갖는 면역학적으로 활성인 펩타이드.
    VWGIRQLRARLQALETLIQNQQRLNLWGXKGKLIXYTSVKWNTSWSGR
    상기 서열식에서, X는 C 또는 S를 의미한다.
  2. 제1항에 있어서, 다음의 아미노산 서열로부터 선택된 약 15개 내지 약 35개의 연속한 아미노산 서열을 갖는 펩타이드.
    RLQALETLIQNQQRLNLWGXKGKLIXYSVKWN
    상기 서열식에서, X는 C 또는S를 의미한다.
  3. 제1항 또는 제2항에 있어서, 사람면역결핍바이러스(HIV)타입의 레트로바이러스 검출에 적합한 펩타이드.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 약 20개 내지 약 30개의 연속한 아미노산을 갖는 펩타이드.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 펩타이드의 한쪽 또는 양쪽 말단에 바이러스 MVP5180의 서열로부터 유래되지 않은 추가의 아미노산을 갖는 펩타이드.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, X가 C의 의미를 갖는 펩타이드.
  7. 제6항에 있어서, 잔기 C에 상응하는 시스템인 잔기가 산화된 상태로 존재하는 펩타이드.
  8. 제6항 또는 제7항에 있어서, 다음의 아미노산 서열을 갖는 펩타이드.
    RLQALETLIQNQQRLNLWGCKGKLIC
  9. 제6항 또는 제7항에 있어서, 다음의 아미노산 서열을 갖는 펩타이드.
    RLQALETLIQNQQRLNLWGCKGKLIS
  10. 제1항 또는 제5항중 어느 한 항에 있어서, 다음의 아미노산 서열을 갖는 펩타이드.
    NQQRLNLWGCKGKLICYTSVKWN
  11. 제1항 또는 제10항중 어느 한 항에 있어서, 합성적으로 제조된 펩타이드.
  12. 제1항 또는 제10항중 어느 한 항에 있어서, 제조합적으로 제조된 펩타이드.
  13. 제1항 내지 제6항 또는 제8항 내지 제10항 중 어느 한 항에 따른 펩타이드를 암호화하는, 분리된 DNA단편.
  14. 제1항 내지 제12항 중 어느 한 항에 따른 하나 이상의 펩타이드를 사용하여 면역결핍증을 일으키는 바이러스에 대한 항체를 검출하기 위한 시험 키트.
  15. 제14항에 있어서, 웨스턴 블롯인 시험 키트.
  16. 제15항에 있어서, ELISA 테스트 또는 형광 항체 검출 시험인 시험 키트.
  17. 면역결핍증을 일으키는 레트로바이러스를 검출하기 위한, 제1항 내지 제12항중 어느 한 항에 따른 펩타이드 및/또는 제13항에 따른 분리된 DNA 단편의 용도.
  18. 백신 제조를 위한, 제1항 내지 제12항중 어느 한 항에 따른 펩타이드의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950003516A 1994-02-23 1995-02-23 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도 KR100230880B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4405810.1 1994-02-23
DE4405810A DE4405810A1 (de) 1994-02-23 1994-02-23 Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung

Publications (2)

Publication Number Publication Date
KR950032278A true KR950032278A (ko) 1995-12-20
KR100230880B1 KR100230880B1 (ko) 1999-11-15

Family

ID=6510992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950003516A KR100230880B1 (ko) 1994-02-23 1995-02-23 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도

Country Status (12)

Country Link
US (4) US5830634A (ko)
EP (1) EP0673948B1 (ko)
JP (1) JP2948121B2 (ko)
KR (1) KR100230880B1 (ko)
AT (1) ATE173275T1 (ko)
AU (1) AU697121B2 (ko)
BR (1) BR9500732B8 (ko)
CA (1) CA2143163C (ko)
DE (2) DE4405810A1 (ko)
DK (1) DK0673948T3 (ko)
ES (1) ES2124922T3 (ko)
NO (1) NO315163B1 (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2107732C (en) * 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
EP0832113B1 (en) * 1995-06-07 2004-05-19 Abbott Laboratories Peptides for hiv-1 detection
US5977299A (en) * 1997-04-07 1999-11-02 Dade Behring Marburg Gmbh Activated peptides and conjugates
WO1998045323A1 (fr) 1997-04-09 1998-10-15 Pasteur Sanofi Diagnostics Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o
DE19718361A1 (de) 1997-05-02 1998-11-05 Dade Behring Marburg Gmbh Immunoassay zur Aviditätsbestimmung von Immunglobulinen
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO1999038887A1 (en) * 1998-01-28 1999-08-05 Universal Healthwatch, Inc. Divergent hiv-1 peptides
WO1999062945A2 (en) * 1998-06-05 1999-12-09 Peptide Solutions, Inc. Peptide antigens for detection of hiv, hcv and other microbial infections
AU748700B2 (en) * 1998-06-12 2002-06-13 Aventis Pasteur HIV virus mimotopes
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
AU2603100A (en) * 1999-01-11 2000-08-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel hiv related peptides
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
ES2525317T3 (es) 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Producción recombinante de inhibidores de la fusión antivirales peptídicos
US8043152B2 (en) * 2003-07-03 2011-10-25 Igt Methods and system for providing paper-based outcomes
ES2383947T3 (es) * 2003-12-19 2012-06-27 Gen-Probe Incorporated Composiciones, métodos y equipos para la detección de ácidos nucleicos del vih-1 y vih-2
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
AU2006214563B2 (en) 2005-02-15 2011-08-18 Thymon, L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2007064859A2 (en) * 2005-11-29 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
US8438898B2 (en) * 2009-07-01 2013-05-14 Edwards Lifesciences Corporation Calibrant infusion fluid source preparation
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328391B1 (en) 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3588248T2 (de) * 1984-10-18 2004-07-01 Institut Pasteur LAV-Antigene und -Peptide
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
CA1247082A (en) 1984-11-09 1988-12-20 Myron E. Essex Assay for detecting infection by human t-cell leukemia virus
AU600658B2 (en) 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IE64785B1 (en) 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
FI861626A (fi) 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
ES2000859A6 (es) 1985-08-12 1988-03-16 Syntex Inc Un metodo para producir un vector de expresion bacteriana para la expresion de proteinas de fusion
US4803156A (en) 1985-09-11 1989-02-07 New York Blood Center Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
NZ217645A (en) 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
GB8525615D0 (en) 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
EP0227169B1 (en) 1985-12-17 1993-03-17 Akzo N.V. Immunochemical reagent
US5079342A (en) 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
EP0320495B1 (fr) 1986-01-22 2000-08-02 Institut Pasteur Procédé de fabrication récombinante des protéines derivées de HIV-2 et culture cellulaire exprimant des protéines de HIV-2
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
AU617088B2 (en) 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
US5034511A (en) 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5030714A (en) 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
EP0525828A3 (en) 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
EP0329671B1 (en) 1986-11-01 1994-01-12 British Bio-Technology Limited Particulate hybrid hiv antigens
EP0269520A3 (fr) 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
JPS63258575A (ja) 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
US5030449A (en) 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0273716B1 (en) 1986-12-30 1993-08-11 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
WO1988005440A1 (fr) 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
EP0300031A4 (en) 1987-01-28 1990-05-14 Ortho Pharma Corp IMMUNE SUPPRESSIVE PEPTIDES AND METHOD FOR THEIR USE.
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
NO881151L (no) 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
SE8701765L (sv) 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
AU620330B2 (en) 1987-05-29 1992-02-20 Smithkline Beckman Corporation Immunodiagnostic assays using chimeric antigens
GB8714802D0 (en) 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE3724016A1 (de) 1987-07-21 1989-02-02 Hans Prof Dr Dr Wolf Methoden fuer die gentechnologische produktion von antigenen sowie deren nutzung in einem neuen ansatz fuer bestaetigungsteste fuer antikoerper am beispiel des humanen immundefizienz-virus (hiv)
IL87391A0 (en) 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
AU2914889A (en) 1987-08-28 1989-04-17 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0307149B1 (en) 1987-09-04 1993-01-07 International Murex Technologies Corporation Solid phase immunoassay for an antibody and biological constructions for use therein
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US4863202A (en) * 1987-09-16 1989-09-05 Oldford William G Fluid connector assembly
EP0311228A3 (en) 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
EP0317804B1 (en) 1987-11-24 1995-10-04 Abbott Laboratories HIV peptides and methods for detection of HIV
EP0323157A3 (en) 1987-12-24 1990-07-25 The University Of Melbourne Antiviral compounds and methods
JPH01179687A (ja) 1987-12-30 1989-07-17 Chemo Sero Therapeut Res Inst Ｈｉｖ融合蛋白質
IL89118A0 (en) 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
US5124255A (en) 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
US5312737A (en) 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
JPH03504722A (ja) 1988-04-07 1991-10-17 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　アラバマ Ｈｉｖ誘導細胞融合およびシンシチウム形成に対するペプチド阻害剤
AU3557889A (en) 1988-04-20 1989-11-24 Trustees Of The University Of Pennsylvania, The Protective peptides derived from human immunodeficiency virus-1 gp160
EP0339389B1 (de) 1988-04-25 1993-09-22 F. Hoffmann-La Roche Ag Diagnose-Hilfsmittel
JP2758900B2 (ja) 1988-05-16 1998-05-28 正憲 速水 ヒト免疫不全ウイルス２型の遺伝子ｒｎａに相補性を示すｄｎａ
ES2072853T3 (es) * 1988-06-09 1995-08-01 Innogenetics Nv Retrovirus hiv-3 y su utilizacion.
EP0345792A3 (en) 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
EP0362909A3 (en) 1988-08-26 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies
EP0434713B1 (en) 1988-09-13 1994-10-12 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
AU640619B2 (en) 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
GB8828098D0 (en) 1988-12-01 1989-01-05 Wellcome Found Peptides
US5223423A (en) 1989-03-31 1993-06-29 United States Of America Characterization of replication competent human immunodeficiency type 2 proviral clone hiv-2sbl/isy
FR2646606B1 (fr) 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
CA2025634A1 (en) 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
EP0493508A1 (en) 1989-09-22 1992-07-08 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
IE904083A1 (en) 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
DE4002636A1 (de) 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh Expression von hiv1- und 2-polypeptiden und deren verwendung
CA2035576A1 (en) 1990-02-07 1991-08-08 Alexander R. Neurath Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1
EP0527760B1 (en) 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
WO1991015512A2 (en) 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
US5013458A (en) 1990-04-06 1991-05-07 Rdp Company Process and apparatus for pathogen reduction in waste
EP0491930B1 (en) 1990-07-12 1997-01-15 The President And Fellows Of Harvard College Primate lentivirus vaccines
CA2050817A1 (en) 1990-09-24 1992-03-25 Emilio A. Emini Hiv-neutralizing rat monoclonal antibodies against pb-1
WO1992005800A1 (en) 1990-09-27 1992-04-16 Syntello Vaccin Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
JP2767078B2 (ja) 1990-10-17 1998-06-18 アメリカ合衆国 Ｈｉｖ―１の分子クローンとその使用法
FR2676071B1 (fr) 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
FR2677364A1 (fr) 1991-06-05 1992-12-11 Pasteur Institut Sequences peptidiques de la glycoproteine externe d'enveloppe du retrovirus hiv-1.
DE4318186C2 (de) 1993-06-01 2002-07-25 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
CA2107732C (en) * 1992-10-06 2003-04-08 Lutz G. Gurtler Retrovirus from the hiv group and its use
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung

Also Published As

Publication number Publication date
US20050271678A1 (en) 2005-12-08
JPH07278189A (ja) 1995-10-24
JP2948121B2 (ja) 1999-09-13
ES2124922T3 (es) 1999-02-16
US5830634A (en) 1998-11-03
BR9500732B1 (pt) 2012-09-04
DE4405810A1 (de) 1995-08-24
NO315163B1 (no) 2003-07-21
CA2143163C (en) 1999-12-28
BR9500732A (pt) 1995-10-24
KR100230880B1 (ko) 1999-11-15
DK0673948T3 (da) 1999-07-26
AU697121B2 (en) 1998-09-24
NO950668D0 (no) 1995-02-22
US6335158B2 (en) 2002-01-01
US7803524B2 (en) 2010-09-28
EP0673948B1 (de) 1998-11-11
US6869608B2 (en) 2005-03-22
CA2143163A1 (en) 1995-08-24
NO950668L (no) 1995-08-24
ATE173275T1 (de) 1998-11-15
EP0673948A1 (de) 1995-09-27
BR9500732B8 (pt) 2014-04-29
US20010009667A1 (en) 2001-07-26
AU1353295A (en) 1995-09-07
US20020123039A1 (en) 2002-09-05
DE59504181D1 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
KR950032278A (ko) 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도
EP0387914B1 (en) Envelope antigens of the human immuno-deficiency virus, and their applications
DI MARZO VERONESE et al. Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15
Mahieux et al. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family
AU595511B2 (en) Recombinant acquired immune deficiency syndrome(aids) viral envelope protein and method of testing for aids
Salminen et al. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
US5637455A (en) HIV-2 virus variants
Horal et al. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
US5288640A (en) Sequences containing the vpu gene and vectors therefore methods of preparation and use
Mathiesen et al. Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides.
Chen et al. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people
Ehrlich et al. Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals
JP3271666B2 (ja) Ｈｔｌｖ―ｉ、ｈｔｌｖ―ｉｉ又は関連レトロウイルスに対する抗体間の識別、新規ペプチド、抗体の検出及び免疫アッセイキット
KR960031609A (ko) Hiv군으로부터의 레트로비루스(mvp-2901/94) 및 그것의 사용
Allan et al. Immunogenic nature of a Pol gene product of HTLV-III/LAV
Rekosh et al. Coexpression of human immunodeficiency virus envelope proteins and tat from a single simian virus 40 late replacement vector.
MXPA01010482A (es) Vacuna anti-vih-1 que comprende toda o parte de la proteina tat de vih-1.
CA2034611C (en) Synthetic peptide compositions with immunoreactivities to antibodies to htlv
Liao et al. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
Schneider et al. The antibody response to the HIV-1 specific" out"(vpu) protein: identification of an immunodominant epitope and correlation of antibody detectability to clinical stages
SHEREFA et al. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993
Shin et al. The use of multiple antigenic peptide (MAP) in the immunodiagnosis of human immunodeficiency virus infection
McPhee et al. Anomalies in Nef expression within the central nervous system of HIV-1 positive individuals/AIDS patients with or without AIDS dementia complex
Windheuser et al. Use of trpE/gag fusion proteins to characterize immunoreactive domains on the human immunodeficiency virus type 1 core protein
HUNT et al. Molecular analyses of HIV-1 group O and HIV-2 variants from Africa.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20120816

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20130820

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20140825

Year of fee payment: 16

EXPY Expiration of term